NCT07204938View on ClinicalTrials.gov

A Long-Term Study of Navenibart in Participants With Hereditary Angioedema

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2031

Study Completion Date

December 31, 2031

Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG

navenibart

Navenibart will be administered as a subcutaneous injection.

Trial Locations (1)

85251

Site 2, Scottsdale

Sponsors
All Listed Sponsors
lead

Astria Therapeutics, Inc.

INDUSTRY

NCT07204938 - A Long-Term Study of Navenibart in Participants With Hereditary Angioedema | Biotech Hunter | Biotech Hunter